Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capivasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 8/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 8/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 8/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | LATS1 | O95835 | 2/20 | 1.00 |
| ▸ | PRKCB | P05771 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | PRKCA | P17252 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | PRKACB | P22694 | 2/20 | 1.00 |
| ▸ | GRK2 | P25098 | 2/20 | 1.00 |
| ▸ | CLK1 | P49759 | 2/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 2/20 | 1.00 |
| ▸ | LIMK2 | P53671 | 2/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capivasertib SCHEMBL390243 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| Capivasertib SCHEMBL31360985 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| Capivasertib SCHEMBL390244 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| Capivasertib SCHEMBL391382 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL386620 | 0.95 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL386619 | 0.95 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL390401 | 0.95 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL391567 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL393210 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL21619156 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| US-20230414626-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-28 | — | — | US | claimed |
| CN-116568330-A | Iron death induction for cancer treatment | 纪念斯隆-凯特琳癌症中心 | 2023-08-08 | — | — | CN | claimed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| WO-2025238662-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 4-AMINO-N-[(1S)-1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL]-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-4-PIPERIDINECARBOXAMIDE AND ITS SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-11-20 | — | — | WO | disclosed |
| WO-2025233516-A1 | METHOD OF INCREASING TIME TO SECOND PROGRESSION AND TIME TO FIRST SUBSEQUENT CHEMOTHERAPY | ASTRAZENECA AB (SE) | 2025-11-13 | — | — | WO | disclosed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| CN-119700983-A | Application of UBR5 in preparation of medicines for treating pigment dermatosis | 中南大学湘雅医院 | 2025-03-28 | — | — | CN | disclosed |
| EP-4519418-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240208925-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | PAGS CO., LTD. (KR) | 2024-06-27 | — | — | US | disclosed |
| CN-118185900-A | Transaminase, preparation method and application thereof, and preparation method of amino-containing compound | 爱斯特（成都）生物制药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117377474-A | Isoquinoline derivatives as antiviral and antitumor agents | RDP制药股份公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230414626-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-28 | — | — | US | disclosed |
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. | 2023-11-09 | — | — | US | disclosed |
| CN-116568330-A | Iron death induction for cancer treatment | 纪念斯隆-凯特琳癌症中心 | 2023-08-08 | — | — | CN | disclosed |
| CN-115397975-A | Improved T cell preparation method | 艾达普特免疫有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | AKT1 327/4885AKT2 591/4885AKT3 709/4885 |
| US-20240208925-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | TP53, EIF2AK2, VHL | AKT1 3101/4885AKT2 3245/4885AKT3 3554/4885 |
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | ICOS, IL2, CD4 | AKT1 72/4885AKT2 89/4885AKT3 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.